10 mg of triamcinolone acetonide non-inferior to 40 mg triamcinolone acetonide in improving pain in symptomatic knee OA.

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2023-03-28 04:00 GMT   |   Update On 2023-03-28 07:21 GMT

10 mg of triamcinolone acetonide (TA) is non-inferior to 40 mg triamcinolone acetonide (TA) in improving pain in patients with symptomatic knee Osteoarthritis suggests a new study published in the BMC Musculoskeletal DisordersIntra-articular (IA) corticosteroid injection is recommended in refractory knee osteoarthritis patients. However, 40-mg of triamcinolone IA every 3 months for 2...

Login or Register to read the full article

10 mg of triamcinolone acetonide (TA) is non-inferior to 40 mg triamcinolone acetonide (TA) in improving pain in patients with symptomatic knee Osteoarthritis suggests a new study published in the BMC Musculoskeletal Disorders

Intra-articular (IA) corticosteroid injection is recommended in refractory knee osteoarthritis patients. However, 40-mg of triamcinolone IA every 3 months for 2 years reduces cartilage volume as compared to saline IA.

A study was done to determine the non-inferiority of 10-mg versus 40-mg of triamcinolone acetonide (TA) for treatment of pain in symptomatic knee osteoarthritis at week 12.

This was a double-blind, randomized, controlled trial conducted in 84 symptomatic knee osteoarthritis patients. The 10-mg or 40-mg of TA were 1:1 randomized and injected to the affected knees. The primary outcome was the 12-week difference from baseline in pain VAS, with a pre-specified lower margin for non-inferiority of 10 mm. The measuring instruments used were: Visual analog scale (VAS: 0–10), modified Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), EuroQol Group 5 Dimensions (EQ5D), Knee Injuries and Osteoarthritis Outcome Score (KOOS) questionnaire, chair standing test and 20-m walking time at baseline, at week 4, and week 12 after randomization. Adverse events were recorded.

Results

Baseline characteristics were similar between two groups.

The mean differences of pain VAS between the two groups at baseline and week 12 were 0.8 with p of 0.002 for non-inferiority.

There were no differences in pain reduction and quality of life improvement between 10-mg and 40-mg groups.

The mean differences (95%CI) of WOMAC, KOOS pain, EQ5D and KOOS quality of life between baseline and week 12 were 0.4. -8.7, 1.3 and 1.8, respectively.

There were significant improvements in pain and quality of life between baseline and week 12 in both groups.

The 10 mg of TA is non-inferior to 40 mg TA in improving pain in patients with symptomatic knee osteoarthritis . Both 10 mg and 40 mg of TA significantly improved pain and quality of life in patients with symptomatic knee osteoarthritis .

Reference:

Utamawatin, K., Phruetthiphat, Oa., Apinyankul, R. et al. The efficacy of intra-articular triamcinolone acetonide 10 mg vs. 40 mg in patients with knee osteoarthritis: a non-inferiority, randomized, controlled, double-blind, multicenter study. BMC Musculoskelet Disord 24, 92 (2023). https://doi.org/10.1186/s12891-023-06191-6

Tags:    
Article Source : BMC Musculoskeletal Disorders

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News